Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

Overview
Date Founded

1983

Headquarters

660 West Germantown Pike,Suite 110,Plymouth Meeting, PA 19462-1111

Type of Company

Public

Employees (Worldwide)

281

Industries

Pharmaceuticals
Biotechnology
Hospitals & Patient Services

Company Description

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Contact Data
Trying to get in touch with decision makers at Inovio Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

Chief Financial & Accounting Officer

Chief Operating Officer & Executive Vice President

Chief Scientific Officer

Senior Vice President, Clinical Operations & Global Integration

Senior Vice President, Engineering Development

Senior Vice President, Regulatory Affairs

Senior Vice President, R&D

Vice President, Alliance & Program Management

Vice President, Clinical Development

Board of Directors

Former Executive Vice President at Merck-Medco Managed Care LLC

President at Georgia Institute of Technology

Founder at Inovio Pharmaceuticals, Inc.

Auditor & Certified Public Accountant at Ernst & Young Global Ltd.

Former President, Chief Executive Officer & Director at Aravive, Inc.

Former Senior Vice President, Human Resources at Merck & Co., Inc.

Executive Vice President at The Wistar Institute

Former Vice President, Marketing at Sanofi

Paths to Inovio Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Inovio Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

ARK Investment Management is a registered investment adviser and privately held investment firm, specializing in thematic investing. The firm is rooted in over thirty years of experience in identifying and investing in disruptive innovations that enable outsized growth as industries transform. Through its open source research process, ARK is able to identify companies that it believes are leading and benefiting from disruptive cross-sector forces and changing how the world works.

Details Hidden

Defender Capital LLC is a private company headquartered in Charlotte, NC. The firm provides investment advice. It was founded in 2011 by John Dean Stamas and Don Gus Stamas. Don Gus Stamas has been the CEO since the company founding.

Details Hidden

MIMI manages two Techinvest funds: (1) MFM Techinvest Technology Fund, which aims to provide capital growth through a portfolio of small-cap equity holdings in technology businesses. The fund is primarily invested in securities quoted on the London Stock Exchange and North American markets; and (2) MFM Techinvest Special Situations Fund which seeks to provide capital growth through a portfolio of equities whose future prospects to do not appear to be yet fully reflected in the current stock market price. The primary focus is on smaller UK companies and particular attention is paid to emerging growth stocks and to recovery situations where a change in a company's underlying dynamics or direction can be expected to lead to an improvement in its reported results.

Recent Transactions
Details Hidden

Inovio Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Inovio Pharmaceuticals, Inc. purchases Bioject Medical Technologies, Inc.

Details Hidden

Inovio Pharmaceuticals, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Transaction Advisors
Underwriter

Advised onInovio Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onInovio Pharmaceuticals, Inc. issued USD Common Stock

Escrow Agent

Advised onInovio Pharmaceuticals, Inc. issued USD Common Stock

Professional

Advised onInovio Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onInovio Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onInovio Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants

Partner at Duane Morris LLP

Legal Advisor

Partner at Olshan Frome Wolosky LLP

Clients

AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 6012, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA.

GeneOne Life Science, Inc. engages in the research, development, and manufacture of deoxyribonucleic acid (DNA) vaccines for the prevention and treatment of diseases. Its products include VGX-3400, VGX-3500, and fluprime. Its service include process cost analysis, sterility testing, research batch production, strain selection, cell bank characterization, and others. It also conduct pre-clinical trials for the treatment of hepatitis C. In addition, it is involved in the contract manufacturing activities for pre-clinical and clinical trials for companies and institutions. The company was founded on January 27, 1976 and is headquartered in Seoul, South Korea.

Key Stats and Financials As of 2018
Market Capitalization
$380M
Total Enterprise Value
$289M
Earnings Per Share
$-1.05
Revenue
$30.5M
Net Profit
$-97M
EBITDA
$-89.1M
EBITDAMargin
-292.29%
Total Debt
$0
Total Equity
$87M
Enterprise Value Sales
9.48x
TEVNet Income
-2.98x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
-9.09%
Five Year Compounded Annual Growth Rate Of Revenue
17.75%
Non-Profit Donations & Grants
$250 - $499
2013
Investments
Details Hidden

Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA.

Suppliers
University of Pennsylvania Computer Software | Philadelphia, PA

The University of Pennsylvania (commonly referred to as Penn or UPenn) is a private, Ivy League university, located in Philadelphia, Pennsylvania, United States. Penn considers itself the fourth-oldest institution of higher education in the United States, as well as the first university in the United States with both undergraduate and graduate studies.

GeneOne Life Science, Inc. Textiles | Seoul, South Korea

GeneOne Life Science, Inc. engages in the research, development, and manufacture of deoxyribonucleic acid (DNA) vaccines for the prevention and treatment of diseases. Its products include VGX-3400, VGX-3500, and fluprime. Its service include process cost analysis, sterility testing, research batch production, strain selection, cell bank characterization, and others. It also conduct pre-clinical trials for the treatment of hepatitis C. In addition, it is involved in the contract manufacturing activities for pre-clinical and clinical trials for companies and institutions. The company was founded on January 27, 1976 and is headquartered in Seoul, South Korea.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals | Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Inovio Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Inovio Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Inovio Pharmaceuticals, Inc..